Lanean...
Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection
In 2016, the US Food and Drug Administration issued a warning about the risk of hepatitis B virus (HBV) reactivation in some patients receiving direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection. HBV reactivation can occur soon after the start of DAA therapy; thus, monitorin...
Gorde:
| Argitaratua izan da: | Gastroenterol Hepatol (N Y) |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Millennium Medical Publishing
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635429/ https://ncbi.nlm.nih.gov/pubmed/29038644 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|